Clinical Trials Logo

Stage IIC Colon Cancer AJCC v8 clinical trials

View clinical trials related to Stage IIC Colon Cancer AJCC v8.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05710406 Recruiting - Clinical trials for Colon Adenocarcinoma

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Start date: May 30, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.